# Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis

> **NCT01066104** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 27 (actual)

## Conditions studied

- Chronic Rhinosinusitis
- Nasal Polyps

## Interventions

- **DRUG:** Xolair placebo
- **DRUG:** Xolair (omalizumab)

## Key facts

- **NCT ID:** NCT01066104
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01066104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01066104, "Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01066104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*